BridgeMD
A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
EU CTIS ID: 2024-511168-10-00
What this study is testing
1. To evaluate the efficacy of KYV-101
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject must be 18 to 60 years of age (inclusive).
- Subject must have a history of diagnosis of PPMS or SPMS
- History of treatment with anti-CD20 mAb with continuing evidence of worsening physical disability over a period of ≥6 months with documented evidence of clinical disability progression within the 2 years prior to inclusion. Patients with active SPMS should also have shown inadequate response or intolerance to another DMT (e.g., sphingosine-1-phosphate (S1P) receptor modulator), subject to availability.
You likely can't join if
- Monophasic disease, radiologically isolated syndrome, clinically isolated syndrome, progressive solitary sclerosis or relapsing-remitting disease as defined by the 2017 McDonald criteria (Thompson 2018).
- History of neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein (MOG) antibody associated disease (MOGAD).
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.